The Role of Anemia in the Progression of Congestive Heart Failure: Is There a Place for Erythropoietin and Intravenous Iron?

Silverberg, Donald S.; Wexler, Dov; Iaina, Adrian; Schwartz, Doron

doi:10.1111/j.1778-428x.2005.tb00121.x

Cited by 36 publications

(41 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10] Anemia is not just a medical but also an important social problem as it leads to decreased work productivity and decreased earning. [11][12][13] It is a vicious cycle where poverty leads to anemia and in turn anemia aggravates poverty.…”

Section: Introductionmentioning

confidence: 99%

Role of socio-demographic and cultural factors on anemia in a tribal population of North Kerala, India

Ismail

Kahkashan

Antony

et al. 2016

Int J Community Med Public Health

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Role of socio-demographic and cultural factors on anemia in a tribal population of North Kerala, India

Ismail

Kahkashan

Antony

et al. 2016

Int J Community Med Public Health

View full text Add to dashboard Cite

“…In mildly anemic chronic heart failure patients, normalization of hemoglobin levels with erythropoietin was shown to have a positive effect on LVEF. 16 In addition to the correction of anemia, other protective effects of erythropoietin may contribute to this improvement in myocardial function. Also, in several experimental models of chronic heart failure, erythropoietin has been described to improve cardiac function.…”

Section: Discussionmentioning

confidence: 99%

Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Ott¹,

Schulz²,

Mehilli³

et al. 2010

Circ: Cardiovascular Interventions

119

View full text Add to dashboard Cite

MD; for the REVIVAL-3 Study Investigators* Background-Erythropoietin improves myocardial function in experimental models of myocardial infarction. The aim of the present study was to determine the value of erythropoietin in patients with acute ST-elevation myocardial infarction. Methods and Results-This randomized, double-blind study included 138 patients admitted with acute ST-elevation myocardial infarction and treated with primary percutaneous coronary intervention. Patients were randomly assigned to receive epoetin-␤ (3.33ϫ104 U, nϭ68) or placebo (nϭ70) immediately and at 24 and 48 hours after percutaneous coronary intervention. The primary end point was left ventricular ejection fraction after 6 months measured by MRI.Other end points included infarct size at 5 days and 6 months. Clinical adverse events (death, recurrent myocardial infarction, stroke, and infarct-related artery revascularization) were investigated at 30 days and 6 months. Left ventricular ejection fraction at 6-month follow-up was 52.

show abstract

“…Entrambi i criteri sono validi per definire la CKD di media o moderata entità (14)(15)(16). È noto che la CKD si associa alla insorgenza di anemia, e che la severità dell'anemia è correlata agli stadi più avanzati di CKD proprio come conseguenza della riduzione nella produzione di eritropoietina endogena (EPO) da parte del rene.…”

Section: La Dimensione Del Problemaunclassified

“…È noto che la CKD si associa alla insorgenza di anemia, e che la severità dell'anemia è correlata agli stadi più avanzati di CKD proprio come conseguenza della riduzione nella produzione di eritropoietina endogena (EPO) da parte del rene. La presenza di entrambi i fattori di rischio, anemia e CKD, grava sulla progressione della CHF (14)(15)(16)(17)(18), configurando in questo modo un circolo vizioso noto come Sindrome anemica cardio-renale ( Fig. 1).…”

Section: La Dimensione Del Problemaunclassified

“…In molti studi di associazione è stato possibile stabilire che la presenza di anemia era associata a una classe funzionale NYHA più severa (14), e a una maggior mortalità (31). Nella maggioranza di questi studi, l'associazione anemia e CHF restava statisticamente significativa anche dopo correzione con altri fattori di rischio come la CKD e l'età mediante l'uso di analisi multivariata.…”

Section: Effetti Dell'anemia Sulla Chfunclassified

See 1 more Smart Citation

The Cardiorenal Anemia Syndrome. Part One: Epidemiology and Clinical Aspects

Rivera

Alibrandi

Lullo³

et al. 2017

Giornale di Tecniche Nefrologiche e Dialitiche

View full text Add to dashboard Cite

The cardiorenal anemia syndrome. Part one: epidemiology and clinical aspects Anemia is a common complication associated with congestive heart failure (CHF) and chronic kidney disease (CKD), and is often reported as a component of the cardiorenal syndrome (CRS). The triad anemia, CHF and CKD has adverse prognostic implications that have led to the reformulation of the syndrome with the term "cardiorenal anemia syndrome" (CRAS). However, there is insufficient agreement about the definition of anemia in the CHF patient, probably due to the heterogeneity of the clinical criteria and the diversity of the patient populations in different studies. The evolution of drug therapy and technology (such as resynchronization of the left ventricle) has not stopped the increase in its incidence nor the associated health system costs. Unfortunately, the current guidelines do not provide specific recommendations for the adequate management of anemia in the cardiorenal patient. The pathophysiological mechanisms at the origin of anemia in CRS are complex and numerous. On the cardiovascular side the most important mechanisms are activation of the sympathetic and renin-angiotensin-aldosterone systems, antidiuretic hormone, and hemodilution, while those associated with CKD include reduction of the endogenous production of erythropoietin, chronic microinflammation, and iron deficiency. Consequently, anemia could represent a new clinical and therapeutic biomarker in CRS. A more comprehensive, 360-degree view, which stratifies the etiological, clinical and pathophysiological aspects, could significantly contribute to improving the prognosis of CRS patients. Keywords: Cardiorenal anemia syndrome (CRAS), Chronic kidney disease (CKD), Congestive heart failure (CHF) Nonostante i diversi specialisti conoscessero molto bene questo problema dal proprio punto di vista, l'approccio multidisciplinare trova sensibili limitazioni principalmente sul piano semantico (1, 2). Per minimizzare tali ostacoli, si rendeva sempre più imperativa la necessità di parlare un linguaggio comune mediante l'adozione di una nuova classificazione che tenesse conto degli aspetti eziologici, fisiopatologici e clinici. La classificazione doveva inoltre distinguere l'incipit e le sequele cliniche della sindrome, differenziare l'organo primariamente coinvolto da quello secondariamente danneggiato, e infine definire la sequenza temporale dell'insorgenza del fenomeno: acuzie o cronicità.Nel 2004, i ricercatori del National Heart, Lung, and Blood Institute (NHLBI), si sono riuniti per cercare di capire le interazioni rene-cuore, creando il Working Group on Cardio-Renal Connections in Heart Failure and Cardiovascular Disease (3). Il gruppo di studio definiva la "sindrome cardio-renale" (CRS), come la situazione nella quale la terapia per alleviare i sintomi congestivi dell'insufficienza cardiaca cronica (Chronic Heart Failure, CHF) è ulteriormente limitata dal declino della funzione renale. Tuttavia, l'assenza di una definizione chiara e la Introduzione L'interazione esistente ...

show abstract

The Role of Anemia in the Progression of Congestive Heart Failure: Is There a Place for Erythropoietin and Intravenous Iron?

Cited by 36 publications

References 69 publications

Role of socio-demographic and cultural factors on anemia in a tribal population of North Kerala, India

Role of socio-demographic and cultural factors on anemia in a tribal population of North Kerala, India

Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

The Cardiorenal Anemia Syndrome. Part One: Epidemiology and Clinical Aspects

Contact Info

Product

Resources

About